The $1.9B Bet That Needles Are Going Extinct in One Corner of Medicine
Chiesi just dropped $1.9 billion on KalVista to grab the only oral pill for acute hereditary angioedema attacks. In a week with five biotech acquisitions, this bet on needles going extinct in HAE might be the smartest of the bunch.
A Pill vs. a Needle: Place Your Bets
Imagine you're having a sudden, painful allergic-type attack. Your face is swelling. Your airway might be next. Now imagine your two treatment options: stab yourself with a needle, or swallow a pill.
That's the choice facing people worldwide with hereditary angioedema (HAE), a rare genetic condition that causes unpredictable episodes of severe swelling. For decades, the only fast-acting treatments were injections. Painful, inconvenient, and frankly terrifying when your throat is closing up.
Italian pharma giant Chiesi just bet $1.9 billion that the pill wins.
What Chiesi Actually Bought
On April 29, Chiesi agreed to acquire KalVista Pharmaceuticals for $27 per share in cash, a 40.3% premium to KalVista's closing price the day before. The deal values the company at approximately $1.9 billion, with no financing conditions attached. Translation: the money is ready, and Chiesi isn't waiting around.
The prize? A drug called Ekterly (sebetralstat), the first and only FDA-approved oral on-demand therapy for acute HAE attacks. Think of it as the EpiPen equivalent for HAE patients, except you don't need to jab yourself. You just take a pill.
Ekterly won FDA approval in July 2025. In its first eight months on the market, it generated $49.1 million in revenue. By February 2026, over 1,700 patients had started treatment in the U.S. alone. For a rare disease drug treating a condition most people have never heard of, those are serious numbers.
Why This Drug Changes the Game
To understand why Chiesi paid nearly $2 billion for a single drug, you need to understand what HAE patients have been dealing with.
HAE attacks strike without warning. Swelling can hit the hands, feet, face, gut, or (most dangerously) the throat. Before sebetralstat, every on-demand treatment required an injection or IV infusion. Picture this: you're at a restaurant, you feel an attack coming on, and your options are to excuse yourself to a bathroom stall to self-inject, or wait until you get home and hope things don't get worse.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Ekterly turns that into "take a pill with your water glass."
The clinical data backs up the convenience story. In the Phase 3 KONFIDENT trial, patients taking sebetralstat felt relief begin in about 1.6 hours, compared to approximately 9 hours on placebo. The open-label extension study showed attacks stopped progressing in a median of just 19.8 minutes. And 83% of patients rated their satisfaction with treatment as "satisfied or better."
Those aren't just good numbers. They represent a fundamentally different patient experience.
The HAE Gold Rush
Chiesi isn't the only company that sees dollar signs in HAE. This market is heating up fast.
BioCryst Pharmaceuticals already dominates the oral prevention side with Orladeyo (berotralstat), a daily pill that reduces the frequency of attacks. Orladeyo is projected to top $600 million in sales in 2025, with 51% year-over-year growth in Q1 2025 alone. The broader HAE therapeutics market is worth roughly $2.8 billion in 2025 and growing at nearly 9% annually, with projections reaching $5.2 billion by 2030.
But there's a key distinction here. Orladeyo prevents attacks. Ekterly treats them once they start. They're complements, not competitors. A patient might take Orladeyo every day and keep Ekterly on hand for breakthrough attacks. Think of it like taking a daily allergy pill but still carrying a rescue inhaler.
Leerink Partners analyst Joseph Schwartz noted that the drug had already captured nearly 20% of the on-demand market within just a few quarters of launch. That kind of early traction is exactly what makes acquirers pull the trigger.
Chiesi's Bigger Ambition
This isn't Chiesi playing small. The family-owned Italian company (yes, family-owned, with a $3.6 billion revenue base) has been on a rare disease shopping spree. It acquired Amryt Pharma in 2023 for up to $1.48 billion, which supercharged its rare disease unit to €763 million in 2024 revenue, up 41% year-over-year. That unit now represents 22% of Chiesi's total sales.
The company has a stated goal of reaching €6 billion in total revenue by 2030. KalVista slots neatly into that plan: a commercially proven, oral, patient-friendly therapy in a growing rare disease market. It's the kind of asset that doesn't require a massive commercial build-out because the patient population is defined, the prescribers are specialists, and the drug is already gaining share.
Chiesi's R&D budget hit a record €829 million in 2024 (about 24% of revenue), signaling they're not just buying growth but also investing in expanding their pipeline. KalVista brings a pediatric program (the KONFIDENT-KID trial for ages 2-11) that's already fully enrolled and ahead of schedule.
An M&A Feeding Frenzy
The KalVista deal didn't happen in a vacuum. It was reportedly the fifth biotech acquisition announced that same week, part of a broader M&A wave washing over the industry in April 2026.
Earlier in the month, Eli Lilly scooped up Kelonia Therapeutics for up to $7 billion. Gilead bought Tubulis for up to $5 billion. Neurocrine acquired Soleno Therapeutics for roughly $2.9 billion. UCB grabbed Neurona Therapeutics for up to $1.15 billion.
See the pattern? Big pharma is buying, and buying aggressively. The common thread: rare diseases, differentiated mechanisms, and late-stage or already-approved assets. Companies with proven drugs (or nearly proven ones) are commanding massive premiums. KalVista's 40.3% premium is actually moderate compared to some of these deals.
Why the frenzy? Patent cliffs are looming for blockbuster drugs across the industry. Meanwhile, rare disease drugs command premium pricing, face less generic competition, and build deep loyalty among specialist prescribers. They're the biotech equivalent of luxury real estate: small markets, but incredibly valuable per square foot.
The 40% Premium Question
Is $1.9 billion a good price? Let's do the napkin math.
If Ekterly reaches peak sales projections, and you assume industry-standard rare disease margins (north of 70%), you're looking at significant potential operating profits annually at maturity. Paying roughly 4x peak sales for an already-approved, fast-growing rare disease asset with pediatric expansion potential? That's aggressive but defensible.
The $66.4 million termination fee suggests Chiesi wants this locked down. And the lack of a financing condition means there's no "oops, we can't get the money together" escape hatch. Both boards approved unanimously, with closing expected in Q3 2026.
For KalVista shareholders, the 40.3% premium is a solid payday. But some might wonder if they left money on the table given the drug's trajectory. When you're already at 20% market share in year one, there's an argument the stock would have gotten there on its own.
Then again, biotech is littered with companies that had great drugs and still found ways to stumble on commercialization. Sometimes the bird in hand (at a 40% premium) beats two in the bush.
What It Means for Patients
This is one of those rare pharma deals where the patient story actually matters to the business thesis. Surveys consistently show that U.S. HAE patients overwhelmingly prefer oral options. That's not a market survey quirk; it's a reflection of how miserable injections are when you're already in pain.
Chiesi has the global infrastructure to expand Ekterly's reach beyond the U.S., which KalVista would have struggled to do alone as a smaller biotech. More countries, more patients, more access.
The deal also signals something important to the broader rare disease community: pharma is willing to pay top dollar for drugs that genuinely improve patient experience, not just clinical endpoints. Ekterly doesn't work faster than injectable options. It works differently, in a way that matters to the people taking it. That distinction is worth $1.9 billion, apparently.
The Bottom Line
Chiesi paid almost $2 billion for a simple idea: patients hate needles. When you can replace an injection with a pill (and the clinical data holds up), you don't just win market share. You potentially reshape an entire treatment paradigm.
The HAE market is still growing. Oral therapies are still displacing injectables. And Chiesi just bought the only oral on-demand option on the market. In a week of aggressive pharma dealmaking, this might be the one that ages best.
Clinical & Regulatory
4 min read
A Patient Died in a Schizophrenia Trial. Now the FDA Wants Answers.
The FDA slammed the brakes on Newron Pharmaceuticals' Phase 3 schizophrenia trial after a patient died at a non-U.S. site. The company says the drug isn't to blame, but the agency wants proof. For one of the few novel approaches to treatment-resistant schizophrenia, the clock is ticking.
